About Us

Striving to make a difference in the lives of millions suffering from debilitating neurodegenerative diseases.

Emtherapro was founded with a singular mission—to advance the state of biomarkers and therapies for neurodegenerative diseases by leveraging advances pioneered by its founders.

True to that vision, Emtherapro seeks to partner with researchers, biotech and pharmaceutical companies, and, healthcare organizations with a shared mission of creating new and effective diagnostics and therapies for neurodegenerative diseases.


kiran_pandey - cropped

Kiran, Pandey, PhD


Kiran brings a dynamic results-oriented leadership to his role as the CEO of Emtherapro.  He has over a decade of experience in healthcare and biotech industry. Prior to Emtherapro, Kiran has held leadership roles in products, strategy, marketing, innovation, analytics at Lumeris, GE Healthcare and McKinsey & Company. Kiran holds a PhD in Biomedical Engineering from University of Michigan.


Allan Levey, MD, PhD

Co-founder & President

Allan is the Robert W. Woodruff Professor of Neurology, and Director of the Goizueta Alzheimer’s Disease Research Center and Goizueta Institute at Emory Brain Health.   He is an internationally recognized expert in Alzheimer’s Disease and related disorders, and a member of the National Academy of Medicine. Dr. Levey holds an MD and PhD degree in Immunology from the University of Chicago.

0092601-18KH Duc Duong, 
Studio Head Shots - Eric Ortlund & Postdoctoral Fellows
F/Biochemistry Department
Jen Colucci, PhD, Senior Research Specialist

Duc Duong

Co-founder & COO

Duc is an expert in proteomics with significant experience in LC-MS/MS technology, data-processing, algorithm development and protein/peptide quantification methods.  Duc has been the Techincal Director of the Emory Integrated Proteomics Core for the last 10+ years. He has contributed to 100+ peer review articles.


Nicholas Seyfried, PhD

Co-founder & CSO

Nick is a Professor of Biochemistry and Neurology at Emory University.  He is a renowned expert in use of quantitative proteomics methods and their application to disease characterization and, analysis of post-translational modifications (PTMs) in neurodegeneration. Dr. Seyfried holds a PhD in Biochemistry from University of Oxford.


Scroll to Top